These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

323 related items for PubMed ID: 27903968

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Second-generation Src/Abl inhibitor bosutinib effectively induces apoptosis in human esophageal squamous cell carcinoma (ESCC) cells via inhibiting Src/Abl signaling.
    Ha YNE, Dai Y, Wufuer D, Pidayi M, Anasihan G, Chen L.
    Neoplasma; 2020 Jan; 67(1):54-60. PubMed ID: 31777258
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Bosutinib Acts as a Tumor Inhibitor via Downregulating Src/NF-κB/Survivin Expression in HeLa Cells.
    Yu L, Guo W, Liu L, Zhang G, Zhang F, Qu Y, Liu Y, Li H, Li H.
    Anat Rec (Hoboken); 2019 Dec; 302(12):2193-2200. PubMed ID: 31569304
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Bosutinib: a dual SRC/ABL kinase inhibitor for the treatment of chronic myeloid leukemia.
    Keller G, Schafhausen P, Brummendorf TH.
    Expert Rev Hematol; 2009 Oct; 2(5):489-97. PubMed ID: 21083014
    [Abstract] [Full Text] [Related]

  • 11. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice.
    Golas JM, Arndt K, Etienne C, Lucas J, Nardin D, Gibbons J, Frost P, Ye F, Boschelli DH, Boschelli F.
    Cancer Res; 2003 Jan 15; 63(2):375-81. PubMed ID: 12543790
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Bosutinib.
    Keller G, Schafhausen P, Brümmendorf TH.
    Recent Results Cancer Res; 2010 Jan 15; 184():119-27. PubMed ID: 20072835
    [Abstract] [Full Text] [Related]

  • 14. Loss of Integrin-Linked Kinase Sensitizes Breast Cancer to SRC Inhibitors.
    Beetham H, Griffith BGC, Murina O, Loftus AEP, Parry DA, Temps C, Culley J, Muir M, Unciti-Broceta A, Sims AH, Byron A, Brunton VG.
    Cancer Res; 2022 Feb 15; 82(4):632-647. PubMed ID: 34921014
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. SKI-606, a Src/Abl inhibitor with in vivo activity in colon tumor xenograft models.
    Golas JM, Lucas J, Etienne C, Golas J, Discafani C, Sridharan L, Boghaert E, Arndt K, Ye F, Boschelli DH, Li F, Titsch C, Huselton C, Chaudhary I, Boschelli F.
    Cancer Res; 2005 Jun 15; 65(12):5358-64. PubMed ID: 15958584
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells.
    Puttini M, Coluccia AM, Boschelli F, Cleris L, Marchesi E, Donella-Deana A, Ahmed S, Redaelli S, Piazza R, Magistroni V, Andreoni F, Scapozza L, Formelli F, Gambacorti-Passerini C.
    Cancer Res; 2006 Dec 01; 66(23):11314-22. PubMed ID: 17114238
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.